The Sepsign Trial For Early Detection Of Sepsis

Decorative image of the Sepsis Learning Lounge

The Sepsign Trial For Early Detection Of Sepsis

SUMMARY

Studies like those referenced in the full article demonstrate that 20% of patients admitted to the ED with infections or uncomplicated sepsis actually experience worsening disease within 72 hours. bioMérieux has launched SepSIGN, a clinical trial with the goal of validating biomarkers that can predict the clinical worsening of adult patients admitted to the ED with a suspected or confirmed infection.

FEATURED EXPERT

Marie-Angélique Cazalis, Associate Staff Scientist at bioMérieux

GET STARTED

Read the article from the Journal of Precision Medicine here.

Read time: 9 minutes

Take me there now!

We want to hear from you!

Your feedback helps us continue to provide resources and content specific to your needs.

Take Our Poll

Global Solutions

VIDAS^®B•R•A•H•M•S PCT™

Detects procalcitonin, a biomarker that aids in the risk assessment for progression to severe sepsis and septic shock. PCT also aids in decision making on antibiotic therapy for patients with lower respiratory tract infections (LRTI).

Learn More